These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Abobotulinum toxin A and onabotulinum toxin A for masseteric hypertrophy: a split-face study in 25 Korean patients.
    Author: Lee SH, Wee SH, Kim HJ, Yeo UC, Lee NH, Lee SW, Cho SB.
    Journal: J Dermatolog Treat; 2013 Apr; 24(2):133-6. PubMed ID: 21888570.
    Abstract:
    Masseter muscle hypertrophy has been treated for cosmetic purposes using several modalities, including injection of type A or type B botulinum toxin into the masseter muscle. In this report, we compared the efficacy and safety of abobotulinum toxin A with onabotulinum toxin A treatment for masseteric hypertrophy in 25 Korean patients with a conversion factor of 2.5:1 through a controlled, split-face, and evaluator-blinded study. The mean grade of clinical improvement based on clinical assessment was 2.8 ± 0.9 for abobotulinum toxin A and 2.7 ± 0.8 for onabotulinum toxin A at 8 weeks after the injection. At 12 weeks after the injection, the mean grade of clinical improvement based on clinical assessment was 2.9 ± 0.9 for abobotulinum toxin A and 2.7 ± 0.8 for onabotulinum toxin A. More pronounced improvement was observed with abobotulinum toxin A than onabotulinum toxin A in three (12%) patients at 8 weeks and five (20%) patients at 12 weeks. We believe that our data can be used as an essential reference for determining the dose of type A botulinum toxin in the treatment of masseteric hypertrophy.
    [Abstract] [Full Text] [Related] [New Search]